Table 4 Stratified analysis for the associations between RAD54L2 and GTF2H1 polymorphisms and the risk of lung cancer
From: Impact of GTF2H1 and RAD54L2 polymorphisms on the risk of lung cancer in the Chinese Han population
SNP | Model | Genotype | Number | adjusted by age and sex | Number | adjusted by age and sex | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Case | Control | OR (95%CI) | p | Case | Control | OR (95%CI) | p | |||
Age ≤ 59 years | Age > 59 years | |||||||||
RAD54L2 rs11720298 | Genotype | AA | 143 | 115 | 1 | 143 | 153 | 1 | ||
GA | 77 | 98 | 0.61 (0.41–0.90) | 0.013* | 108 | 87 | 1.16 (0.81–1.67) | 0.408 | ||
GG | 15 | 21 | 0.57 (0.28–1.16) | 0.120 | 20 | 25 | 0.8 (0.42–1.51) | 0.489 | ||
dominant | AA/GG + GA | 143/92 | 115/119 | 0.60 (0.42–0.87) | 0.007* | 143/128 | 153/122 | 1.09 (0.77–1.53) | 0.625 | |
recessive | GA + AA/GG | 220/15 | 213/21 | 0.70 (0.35–1.39) | 0.306 | 251/20 | 250/25 | 0.75 (0.40–1.39) | 0.362 | |
log-additive | 0.69 (0.51–0.92) | 0.012* | 1.00 (0.77–1.30) | 0.991 | ||||||
RAD54L2 rs4687592 | Genotype | CC | 106 | 129 | 1 | 120 | 110 | 1 | ||
TC | 96 | 82 | 1.41 (0.95–2.10) | 0.085 | 120 | 128 | 0.85 (0.59–1.22) | 0.377 | ||
TT | 33 | 24 | 1.74 (0.96–3.13) | 0.066 | 31 | 37 | 0.78 (0.45–1.34) | 0.366 | ||
dominant | CC/TT + TC | 106/129 | 129/106 | 1.49 (1.03–2.14) | 0.034* | 120/151 | 110/165 | 0.83 (0.59–1.17) | 0.297 | |
recessive | TC + CC/TT | 202/33 | 211/24 | 1.50 (0.85–2.63) | 0.162 | 240/31 | 238/37 | 0.85 (0.51–1.41) | 0.522 | |
log-additive | 1.35 (1.03–1.76) | 0.028* | 0.87 (0.68–1.12) | 0.284 | ||||||
RAD54L2 rs9864693 | Genotype | CC | 70 | 97 | 1 | 73 | 74 | 1 | ||
GC | 119 | 101 | 1.60 (1.06–2.40) | 0.025* | 156 | 146 | 1.09 (0.73–1.61) | 0.688 | ||
GG | 46 | 37 | 1.75 (1.03–2.99) | 0.039* | 42 | 55 | 0.80 (0.47–1.34) | 0.391 | ||
dominant | CC/GG + GC | 70/165 | 97/138 | 1.64 (1.12–2.40) | 0.012* | 73/198 | 74/201 | 1.01 (0.69–1.47) | 0.972 | |
recessive | GC + CC/GG | 189/46 | 198/37 | 1.35 (0.83–2.17) | 0.226 | 229/42 | 220/55 | 0.75 (0.48–1.18) | 0.215 | |
log-additive | 1.37 (1.05–1.77) | 0.019* | 0.91 (0.71–1.18) | 0.488 | ||||||
GTF2H1 rs4150667 | Genotype | CC | 98 | 118 | 1 | 127 | 120 | 1 | ||
TC | 109 | 97 | 1.38 (0.94–2.03) | 0.100 | 122 | 125 | 0.92 (0.64–1.31) | 0.626 | ||
TT | 28 | 20 | 1.67 (0.88–3.15) | 0.115 | 22 | 30 | 0.67 (0.36–1.23) | 0.194 | ||
dominant | CC/TT + TC | 98/137 | 118/117 | 1.43 (0.99–2.07) | 0.055 | 127/144 | 120/155 | 0.87 (0.62–1.22) | 0.411 | |
recessive | TC + CC/TT | 207/28 | 215/20 | 1.42 (0.78–2.61) | 0.254 | 249/22 | 245/30 | 0.70 (0.39–1.25) | 0.227 | |
log-additive | 1.32 (1.00-1.75) | 0.048* | 0.85 (0.66–1.11) | 0.238 | ||||||
BMI ≤ 24 kg/m 2 | BMI > 24 kg/m 2 | |||||||||
GTF2H1 rs4150667 | Genotype | CC | 68 | 65 | 1 | 33 | 93 | 1 | ||
TC | 62 | 58 | 1.02 (0.62–1.67) | 0.955 | 37 | 76 | 1.36 (0.77–2.40) | 0.286 | ||
TT | 3 | 15 | 0.18 (0.05–0.65) | 0.009* | 11 | 12 | 2.44 (0.97–6.18) | 0.059 | ||
dominant | CC/TT + TC | 68/65 | 65/73 | 0.84 (0.52–1.36) | 0.474 | 33/48 | 93/88 | 1.51 (0.88–2.58) | 0.135 | |
recessive | TC + CC/TT | 130/3 | 123/15 | 0.18 (0.05–0.63) | 0.008* | 70/11 | 169/12 | 2.09 (0.87–5.06) | 0.100 | |
log-additive | 0.70 (0.47–1.04) | 0.077 | 1.49 (0.99–2.24) | 0.059 | ||||||
Non-smokers | Smokers | |||||||||
RAD54L2 rs11720298 | Genotype | AA | 92 | 88 | 1 | 138 | 56 | 1 | ||
GA | 62 | 75 | 0.72 (0.45–1.15) | 0.167 | 86 | 41 | 0.84 (0.52–1.37) | 0.485 | ||
GG | 7 | 16 | 0.28 (0.11–0.75) | 0.011* | 18 | 11 | 0.69 (0.30–1.55) | 0.367 | ||
dominant | AA/GG + GA | 92/69 | 88/91 | 0.63 (0.40–0.99) | 0.047* | 138/104 | 56/52 | 0.81 (0.51–1.28) | 0.362 | |
recessive | GA + AA/GG | 154/7 | 163/16 | 0.33 (0.13–0.85) | 0.021* | 224/18 | 97/11 | 0.74 (0.33–1.63) | 0.448 | |
log-additive | 0.62 (0.43–0.89) | 0.011* | 0.83 (0.59–1.18) | 0.305 | ||||||
Drinkers | Non-drinkers | |||||||||
RAD54L2 rs11720298 | Genotype | AA | 66 | 49 | 1 | 251 | 75 | 1 | ||
GA | 40 | 41 | 0.70 (0.39–1.24) | 0.217 | 95 | 66 | 0.72 (0.47–1.09) | 0.118 | ||
GG | 3 | 13 | 0.17 (0.05–0.63) | 0.008* | 21 | 14 | 0.76 (0.36–1.57) | 0.455 | ||
dominant | AA/GG + GA | 66/43 | 49/54 | 0.57 (0.33–0.99) | 0.045 | 151/116 | 75/80 | 0.72 (0.48–1.08) | 0.110 | |
recessive | GA + AA/GG | 106/3 | 90/13 | 0.20 (0.05–0.71) | 0.013 | 246/21 | 141/14 | 0.87 (0.43–1.78) | 0.708 | |
log-additive | 0.54 (0.35–0.85) | 0.008* | 0.80 (0.59–1.09) | 0.162 | ||||||
RAD54L2 rs4687592 | Genotype | CC | 38 | 47 | 1 | 124 | 77 | 1 | ||
TC | 50 | 45 | 1.37 (0.76–2.48) | 0.295 | 114 | 66 | 1.08 (0.71–1.65) | 0.706 | ||
TT | 21 | 11 | 2.54 (1.07-6.00) | 0.034* | 29 | 13 | 1.43 (0.70–2.92) | 0.329 | ||
dominant | CC/TT + TC | 38/71 | 47/56 | 1.60 (0.91–2.79) | 0.101 | 124/143 | 77/79 | 1.14 (0.77–1.70) | 0.518 | |
recessive | TC + CC/TT | 88/21 | 92/11 | 2.15 (0.97–4.79) | 0.061 | 238/29 | 143/13 | 1.38 (0.69–2.74) | 0.365 | |
log-additive | 1.53 (1.03–2.28) | 0.035* | 1.15 (0.85–1.56) | 0.366 | ||||||
Lung squamous cell carcinoma | Lung adenocarcinoma | |||||||||
GTF2H1 rs3802967 | Genotype | CC | 59 | 133 | 1 | 65 | 133 | 1 | ||
TC | 79 | 263 | 0.67 (0.45-1.00) | 0.051 | 96 | 263 | 0.74 (0.51–1.09) | 0.128 | ||
TT | 36 | 114 | 0.70 (0.43–1.15) | 0.158 | 51 | 114 | 0.94 (0.60–1.47) | 0.780 | ||
dominant | CC/TT + TC | 59/115 | 133/377 | 0.68 (0.46–0.99) | 0.045* | 65/147 | 133/377 | 0.80 (0.56–1.14) | 0.224 | |
recessive | TC + CC/TT | 138/36 | 396/114 | 0.90 (0.59–1.38) | 0.629 | 161/51 | 396/114 | 1.13 (0.77–1.66) | 0.526 | |
log-additive | 0.82 (0.64–1.05) | 0.118 | 0.96 (0.76–1.20) | 0.694 | ||||||